|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.55(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.06 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 625 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
10,995 |
133,280 |
276,351 |
867,449 |
Total Sell Value |
$400,850 |
$4,028,847 |
$7,154,366 |
$20,637,629 |
Total People Sold |
2 |
4 |
4 |
6 |
Total Sell Transactions |
2 |
8 |
13 |
39 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Heffernan Michael Thomas |
Director |
|
2020-01-21 |
4 |
D |
$21.56 |
$16,968 |
D/D |
(787) |
106,012 |
|
- |
|
Heffernan Michael Thomas |
Director |
|
2020-01-21 |
4 |
AS |
$21.84 |
$6,476,863 |
D/D |
(295,287) |
106,799 |
|
9% |
|
Heffernan Michael Thomas |
Director |
|
2020-01-21 |
4 |
OE |
$5.73 |
$1,578,403 |
D/D |
275,463 |
402,086 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2020-01-21 |
4 |
D |
$21.56 |
$4,614 |
D/D |
(214) |
73,342 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2020-01-21 |
4 |
D |
$21.56 |
$4,614 |
D/D |
(214) |
151,173 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2020-01-14 |
4 |
AS |
$23.87 |
$31,532 |
D/D |
(1,321) |
35,716 |
|
-5% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2020-01-10 |
4 |
D |
$23.30 |
$16,357 |
D/D |
(702) |
37,037 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2020-01-02 |
4 |
D |
$20.58 |
$22,453 |
D/D |
(1,091) |
171,686 |
|
- |
|
Freund John Gordon |
Director |
|
2019-12-02 |
4 |
A |
$0.00 |
$0 |
I/I |
8,625 |
8,625 |
|
- |
|
Freund John Gordon |
Director |
|
2019-12-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(574,916) |
0 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2019-11-29 |
4 |
D |
$21.73 |
$101,653 |
D/D |
(4,678) |
172,777 |
|
- |
|
Freund John Gordon |
Director |
|
2019-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
8,423 |
34,788 |
|
- |
|
Freund John Gordon |
Director |
|
2019-11-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(575,000) |
574,916 |
|
- |
|
Hirsch David |
Director |
|
2019-11-08 |
4 |
S |
$19.33 |
$483,250 |
D/D |
(25,000) |
17,117 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2019-11-08 |
4 |
S |
$19.44 |
$486,000 |
D/D |
(25,000) |
73,556 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2019-11-08 |
4 |
OE |
$5.73 |
$143,250 |
D/D |
25,000 |
98,556 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2019-11-07 |
4 |
AS |
$18.41 |
$1,216,774 |
D/D |
(64,821) |
177,455 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2019-11-07 |
4 |
OE |
$8.22 |
$532,829 |
D/D |
64,821 |
242,276 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2019-09-16 |
4 |
D |
$12.44 |
$9,156 |
D/D |
(736) |
43,394 |
|
- |
|
Hirsch David |
Director |
|
2019-08-29 |
4 |
S |
$11.65 |
$257,535 |
D/D |
(22,106) |
42,117 |
|
- |
|
Hirsch David |
Director |
|
2019-08-29 |
4 |
OE |
$9.33 |
$185,228 |
D/D |
19,853 |
64,223 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2019-08-09 |
4 |
D |
$11.24 |
$17,051 |
D/D |
(1,517) |
73,556 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2019-08-09 |
4 |
D |
$11.24 |
$17,051 |
D/D |
(1,517) |
151,387 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2019-08-09 |
4 |
D |
$11.24 |
$10,330 |
D/D |
(919) |
177,455 |
|
- |
|
Heffernan Michael Thomas |
Director |
|
2019-08-09 |
4 |
D |
$11.24 |
$53,716 |
D/D |
(4,779) |
126,623 |
|
- |
|
391 Records found
|
|
Page 9 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|